Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018. The company announced its fiscal 2018 first-quarter results after the market closed on Monday. Frankly, most investors weren’t too interested in the financial numbers. But there was definitely a desire to know more about what is going on with the potential launch of Epidiolex and GW’s cannabinoid pipeline.

View Original Article Here